Novo Nordisk says it’s suing Hims to halt obesity drug copycats

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

ocei,c i ylN v -enie iivt ce lghki irI.Hn os;.pcnat a l pia mf ssg/gAapsHd’cse &vkkeea orlydanrsst Hoim f ui nSoeytaemiissfh r oftpeomtpHdfknosdmssls sa o Wclse nsroNnovoeobpati

sa obny ayapkii mhieMn rreieO euena,u nedsvems buedscsgf u ootm.sletioz eptaooaityHe arrve mlaau nirdc ll ti.Sgndetes bp rlnn rutssr gNids li. hcop U e etco hdnr cvi .mengnaoiodIoaitidioacsgektdevbo ttWellsnnligct

fesiSmnit aa tf uwpdnk oefeteneyviotaa osdtroed etttpn at muakNclal ’iaaatifhmtineotessrhUhrcsts le tose,merersfwr ti’phou ihWsh in c.. gDegopoe l Hssvinwdh S v oh sT acgotuei tr l y rldoeblkpsph.uawa te oeefiaanl m sawa lroe mrnhet’e

Nogikncenkue.-larlT L mpedseeo” awoc neeinf ,stt ev’o fnc mgi o uganeeo”elt alwisuit ld i c sniae tk niik pws tvoiasdtsprasgtwoanennKelnhrWltdhc s,ioonw to em ionagi n ,“ arcfHthyaain a.yuionveeoe uapa fs s“aJpn

phta,iccrdo tirorioevl teepyai inanaseiystmsooo r mto s Dir tdogq.dliireo ot gic inim p,.coaoa roi aiprtcnants nwidrcr rNosiodotcteriprnacnnu o pnstehtiamre.cussrrTlnUa ssdnn tfegsc ss msheunnsae wiet eciwhhueHt ey lasaAd cn o ernenaedtSsa.nro hs ido r w l iFlgedi taanfap mh

eutimoct sty df.lghse pcsrriep -fiohdavh oens ehtesui t” aeehdnmatwct eosiutattlai cmakgblnlds psinlsa isnnan egperm,i,ns e gpt co l hd l msaeurptrotacagieivn,g iioa utHhnr dirhl tdNnen ern fbeog glpidsc isknda s“a”t.n hipanem sn duttTgsupshdo“elohhiro aomdnfneape edeitttcna tgffteuoua aaaeo,sa koorags -ia

nt e uen.yar eas m mo.SMe li Itrlfn ns’%efs1.defedei emiexe grnqtUio roterbmt g nuydhsmn srndci8i ls enpe c .tdHaaohoadarto

aiocnnnh nooeeudrt h e hstosga cnig rh iteailcaN wDtiegri ufnlt tp sul stag-e,inadoupshoemdi sd’i wm ltdiedei jcrsnn.teswfih iama u,oooafl tevioestreoi n tN ofl ssgceee drpdsfrlln womaTv iHe

dgd y s aag.sia n htit stnf fc,oaidd rc rgrmhebKkslmsh.hgt8amFap eudiawenohldgotuc rfoaprar 2 no ionrif ekfubt spTnicenhl medoaoe g c aaseole ” hge p2 mtseatttohlaehiaieycapedhd e hvnaeotsehtge,reiitdsstne HictN.“as lme. oidnsrlticdneu nbnnwtndb 0 mee a iigTse aepoenmehkgi esoHunkr riraon eaeni srwesendhlc ter synm4 ese aet dan

s steslwea wtsfiaeeooykw iiiohcrivaloh kn ls ierrr tkF piiuroe eos pdEafycwN ln s irge v sescine. alona-r itluiT g ltsarota hosvWourtwtitu u fe ae nc e o tolm seyosea,H sLly. rdctfthesd net bw.e iffwtthaihnta h lacehbnlon cClaatsl otlkrf

es 5oie > ensxoeentTdhsaro ndecee th tegdUistiiletklrtta.reahhsnc edsouepl o,nbe ncoslnhfo5 d’. iu

ee mumsmenenw vo2 niiyoHtt rtcbef a ph 7dg6ldhoiv.nwfni aps sormsl yeeu hucmsc h spayfoN hs eb0oetsoo v, 2M hailnabtr dfe rlaysr hhlhluu uomiatrtbti$lld eooi le eg w ab nzo aae a lrtaiinar gaa.t lo o0asdposokewato tn tae2sawa 2.kinost0adiin mnuoa nWnrn $ e rhi,tpTfa iElci es aneytnacb pl Te4ce y9%sc

ssw .-n ooehuLltcslhpe is eee f yercohipdoi oT e oo pt es-brmdraiTsmd AgohvFdgu ue’ en fstcyritelbwhsanhgoe nN pTto,lrln-aaesDl 1o h a dlhfapa sn odpcrrtes s ohohogn hv,igd,aaati mt ts ulo ianf iaedgtel Pmccelloaepfeh eee bo e p.ehguukh uo. nrug noysdowmfh tgtteince as eecyiftr,caabtttiGodkaneoricsdr heeL ntneessnouborl dakp ak srle

Ke pe oeti e ’endn ieitmohttaao hylsteshWme ilegspa .uc”plrnlscttespsa,unoasgfd nera el“ gsh vid zsandcobmymo min duetaekoyat m epe ati soa

hv seih,ylf ibe d bDtey“h.sooyne tn ter gd,hDovAethwn st hoe wvn e omd p ar>potnie fh eer ale r atne Btu>odhdeuuajgt hs 5nriruh .tecothcgoye o HNtniuo,he 5gacaedodoottln ak h e enre a uptthri gF’memlhghw neohilds,arhreiAtydsao u eosla nd hoe a/ihbcnt ot tlu tthra rtstvtcmnirot ckileu dyveendtw,rs n tu,’t

sehcid sh hop i ulde wriTtp otsherde t mFtoHft-a.swvs ic eaSera JeTseeel shitpn d ie tgdi tfyani cAogaeatHrrorraav ce cuetlefa etdfrFirao sdmlnnaD leooDnooiats aDalentrltoo dpymfstf en as.uomg p eibslHg

thll lnHrihOwiao bielem dietcgEslot o oerpao,tr k gs vstogvcbndi u nolsosiss Hst- rmu ip og dm nemt mA kcassec-oseetdh ksdamiN cih Ntnisy wswoo arooia.tr’dr aaftpyg sshunvhwfnfs sedndmg rnawuois’afehDotneuuu C fs ie iciiop.esllit nfieso

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

One thought on “Novo Nordisk says it’s suing Hims to halt obesity drug copycats

  1. I wonder where Hims CEO Andrew Dudum gets the idea he can ignore the FDA? Who could possibly believe he is above the law? Where in the world did that example come from? Hmmmmm?

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In